Travere (TVTX) Surges 11.6%: Is This an Indication of Further Gains? [Yahoo! Finance]
Orchestra BioMed Holdings, Inc. - Ordinary Shares (OBIO)
Company Research
Source: Yahoo! Finance
The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 37.5% gain over the past four weeks. Last month, the FDA granted full approval to the company's marketed product, Filspari (sparsentan), an oral non-immunosuppressive drug, for treating primary IgA nephropathy (IgAN) in adults who stand at high/low risk of disease progression. The approval made Filspari the only non-immunosuppressive drug available for this condition. This might have driven the recent share price rally. This drug developer is expected to post quarterly loss of $0.71 per share in its upcoming report, which represents a year-over-year change of +39.3%. Revenues are expected to be $59.42 million, up 60.2% from the year-ago quarter. While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-t
Show less
Read more
Impact Snapshot
Event Time:
OBIO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OBIO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OBIO alerts
High impacting Orchestra BioMed Holdings, Inc. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
OBIO
News
- Orchestra BioMed Holdings, Inc. (NASDAQ: OBIO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $14.00 price target on the stock.MarketBeat
- Orchestra BioMed Holdings Third Quarter 2024 Earnings: Beats Expectations [Yahoo! Finance]Yahoo! Finance
- We Think Orchestra BioMed Holdings (NASDAQ:OBIO) Needs To Drive Business Growth Carefully [Yahoo! Finance]Yahoo! Finance
- Orchestra BioMed Holdings, Inc. (NASDAQ: OBIO) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $20.00 price target on the stock.MarketBeat
- Orchestra BioMed Holdings, Inc. (OBIO) Reports Q3 Loss, Tops Revenue Estimates [Yahoo! Finance]Yahoo! Finance
OBIO
Sec Filings
- 11/12/24 - Form 10-Q
- 11/8/24 - Form SC
- 10/23/24 - Form SC
- OBIO's page on the SEC website